

- for myocardial infarction, 1595–1596, 1597t, 1603
 overdose/poisoning with, 473e-11t
 for Prinzmetal's variant angina, 1598
 for pulmonary edema, 1763
 tolerance to, 1588
- Nitric oxide**
 in asthma, 1674, 1676
 in blood vessels, 265e-2, 265e-4
 in cirrhosis, 286
 in clitoral engorgement, 330
 in erection, 324, 325f
 in gastric mucosal integrity, 1912
 in shock, 1745, 1747
 in swallowing, 255
- Nitric oxide synthase.** *See* Endothelial nitric oxide synthase (eNOS)
- Nitric oxide therapy,** 1739, 1739t, 1743
- Nitrites,** 473e-11t, 637
- Nitroblue tetrazolium dye test,** 423
- Nitrofurantoin**
 action of, 931t, 932f, 933, 944
 adverse effects of, 938t, 944
 common, 867t
 eosinophilia, 422, 1687
 folate deficiency, 646t
 in G6PD deficiency, 656t
 hepatotoxicity, 2028
 neuropathy, 2687t
 for cystitis, 866, 867, 867t
 indications for, 941t, 944
 in pregnancy and lactation, 937t
 prophylactic, 945t
 resistance to, 931t, 934, 941t, 944
 for urinary tract infections, 975t, 1029
- Nitrogen dioxide exposure,** 1692t
- Nitrogen mustard.** *See* Mechlorethamine (nitrogen mustard)
- Nitrogen oxides, as chemical terrorism agents,** 262e-1t
- Nitroglycerin**
 adverse effects of, 1588, 1603
 drug interactions of, 43
 for ergot alkaloid overdose/poisoning, 473e-8t
 for heart failure, 1510t, 1608
 for hypertensive emergencies, 1627t
 for hypothermia, 478e-3
 intravenous, 1607
 for ischemic heart disease, 1588, 1588t
 metabolism of, 34
 for myocardial infarction, 1603, 1607
 for Prinzmetal's variant angina, 1598
 for pulmonary edema, 1761f, 1763
- Nitroimidazoles,** 205e-7
- Nitroprusside**
 for adrenergic crisis, 1627
 for aortic dissection, 1641
 for ergot alkaloid overdose/poisoning, 473e-8t
 for heart failure, 1510t
 for hypertensive emergencies, 1626t, 1627
 for pulmonary edema, 1763
 therapeutic monitoring of, 2765t
- Nitroprusside ketone reaction,** 318
- Nitrosoureas,** 103e-8, 621, 1797
- Nitrous oxide**
 adverse effects of, 635
 as greenhouse gas, 151e-2t, 151e-3f
 inhalation of, cobalamin deficiency in, 646
 for sickle cell painful crisis, 635
- NIV.** *See* Noninvasive ventilation (NIV)
- Nivolumab,** 103e-21, 521
- Nixon's method, splenic percussion,** 411
- Nizatidine,** 263, 1920, 1920t
- Njovera.** *See* Endemic syphilis
- NK cells.** *See* Natural killer (NK) cells
- NK T cells.** *See* Natural killer (NK) T cells
- NLM (National Library of Medicine),** 14e-4t
- NLRC4/IPAF inflammasome,** 145e-8f
- NLRP1 gene,** 372e-8t
- NLRP1/NALP1b inflammasome,** 145e-8f
- NLRP2/NALP3 inflammasome,** 145e-8f
- NLRP3 gene,** 372e-8t, 2215
- NLRs (NOD-like receptors),** 145e-7, 145e-8f, 372e-2, 372e-5t
- NLST (National Lung Cancer Screening Trial),** 509–510, 510t
- NMDA receptor antibodies,** 444e-9, 614t, 615f, 617, 2607
- NMS (neuroleptic malignant syndrome),** 2624, 2643
- NMYC gene mutations,** 101e-2t, 101e-3
- NO-1,** 167e-2
- Nocardia* spp.,** 1084, 1084t, 1086
- Nocardia* spp. infections,** **1084**
 actinomycetoma, 1085–1086, 1086f, 1087t
 antimicrobial resistance in, 1084t
 in cancer patient, 488, 488t
 chronic meningitis, 907t
 clinical features of, 308e-6f, 1084–1086, 1085f
 diagnosis of, 150e-1, 150e-2t, 1086–1087, 1086f
 epidemiology of, 1084
 in HIV infection, 1084
 pathogenesis of, 1084
 in transplant recipient, 926
 treatment of, 1084t, 1087–1088, 1087t
- Nocebo effect,** 89
- Nociceptin/orphanin receptors,** 468e-1t
- Nociceptive pain,** 60
- Nociceptor(s),** 87
- Nociceptor(s), primary afferent,** 87f, 88f, 89f
- Nociceptor-induced inflammation,** 88, 88f
- Nocturia,** 1872
- NOD2 gene mutations,** 1949, 1950t, 2215
- Nodal marginal zone B-cell lymphoma,** 135e-2, 707
- NOD-like receptors (NLRs),** 145e-7, 145e-8f, 372e-2, 372e-5t
- NOD proteins,** 145e-7, 372e-6t, 1752
- Nodular vasculitis,** 366
- Nodule,** 127, 339t, 340f. *See also* Papulonodular skin lesions
- Nogo,** 444e-8
- Noise exposure,** 224–225, 225t
- Noma (cancrum oris),** 236, 487, 1097
- NOMID (neonatal-onset multisystem inflammatory disease),** 2213t, 2215
- Non-24 hour sleep-wake rhythm disorder,** 193
- Nonaka's distal myopathy,** 462e-12, 462e-13t
- Nonalcoholic fatty liver disease (NAFLD),** **2054**
 cirrhosis due to, 2060
 clinical features of, 2056
 diagnosis of, 2055–2056, 2056t
 epidemiology of, 2054
 etiology of, 2054, 2055t, 2056t
 global considerations in, 2057
 metabolic syndrome and, 2452
 obesity and, 415e-6
 pathogenesis of, 2055
 treatment of, 2056–2057
- Nonalcoholic steatohepatitis (NASH)**
 cirrhosis due to, 2060
 diagnosis of, 366e-5f, 1993t
 etiology of, 2055t, 2056t
 genetic considerations in, 2518
 hepatocellular carcinoma and, 545t
 natural history of, 2054
 pathogenesis of, 2055
- Nonallelic (locus) heterogeneity,** 435–436, 436t
- Nonbacterial thrombotic endocarditis (NBTE),** 817
- Noncompliance,** 36
- Nondisclosure of information,** 17e-1
- Nonexercise activity thermogenesis,** 415e-5
- Nonhistone proteins,** 427f
- Non-Hodgkin's lymphoma.** *See also* Lymphoid malignancies
 approach to the patient, 700–701
 classification of, 695, 696t
 clinical features of, 702t
 epidemiology of, 697
 etiology of, 697, 697t
 genetic considerations in, 101e-3t
 HSCT for, 139e-5t, 139e-6
 HTLV-1 and, 697, 707
 infections in, 484, 484t, 486t
- International Prognostic Index for,** 700–701, 701f, 701t
 late consequences of treatment of, 623, 624t
 during pregnancy, 124e-4
 primary central nervous system. *See* Primary central nervous system lymphoma (PCNSL)
 renal involvement in, 1859
 rituximab for, 372e-30
 skin manifestations of, 76e-5f, 366, 372, 501f
 splenomegaly in, 411
 staging of, 700t, 702t
 thiopurine-associated, 1962
- Nonhuman primates, bite-wounds from,** 167e-2, 167e-3t
- Non-insulin-dependent diabetes mellitus (NIDDM).** *See* Diabetes mellitus, type 2
- Noninvasive ventilation (NIV)**
 advantages and disadvantages of, 1742t
 contraindications for, 1707, 1741t
 for COPD, 1707, 1740
 for hypoventilation, 1722
 for pulmonary edema, 1763
 variables in, 1742t
- Nonocclusive mesenteric ischemia,** 1979–1980, 1980t
- Nonoliguria,** 293
- Nonoxynol 9,** 863, 1009
- Nonreactive military tuberculosis,** 1112
- Nonseminoma**
 mediastinal, 591
 testicular. *See* Testicular cancer
- Nonsense mutation,** 433f
- Nonsteroidal anti-inflammatory drugs (NSAIDs)**
 action of, 1912
 adverse effects of
 bleeding, 404
 colitis, vs. IBD, 1957
 cross-sensitivity and, 385
 cutaneous, 360, 361, 377, 378, 381
 diarrhea, 267
 edema, 252, 253t
 gastrointestinal bleeding, 277, 2232, 2232t
 gastrointestinal ulcers, 262. *See also* Peptic ulcer disease, NSAID-induced
 hyperkalemia, 64e-2, 310
 hypertension, 1617t
 immunologic factors in, 377
 in ischemic heart disease, 1590
 in myocardial infarction, 1604
 nail disorders, 380
 proximal ileal stricture, 1884f
 renal, 90–91, 291, 1800, 1801f, 1821, 1857, 2232
 SJS or TEN, 383. *See also* Stevens-Johnson syndrome (SJS); Toxic epidermal necrolysis (TEN)
 in SLE, 2130t, 2132
 vasculitis, 382
 for ankylosing spondylitis, 2172
 for back pain, 119
 for calcium pyrophosphate deposition disease, 2236
 for colorectal cancer prevention, 539
 for dementia prevention, 2602
 drug interactions of, 43, 103e-11t, 103e-14, 2130t
 for dysmenorrhea, 338–339
 for episcleritis and scleritis, 200
 for fever, 126
 for fever of unknown origin, 141
 gastric protection with, 1923–1924, 1924t
 for gout, 2234
 for menorrhagia in perimenopause, 2382
 for migraine, 2590, 2592t
 for nephrogenic diabetes insipidus, 304
 for osteoarthritis, 2231–2232, 2232t
 for pain, 60, 90–91, 91t
 for phototoxicity, 390
 for polyposis syndromes, 539
 for reactive arthritis, 2175
 for rheumatic fever, 2152–2153
 for rheumatoid arthritis, 2145